Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Henan Center for Disease Control and Prevention | OTHER_GOV |
Not provided
Not provided
Not provided
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.
The clinical trial will be a single-center, randomized, blind, controlled study in which two dose levels of vaccine will be tested in healthy adults aged 18 to 49 years and 50 years and older, with progression from low dose level to high dose level and younger age group to the older age group based on assessment of safety and tolerability. The younger cohort (aged 18 to 49 years) will consist of 60 subjects, 30 per dose level, and these 30 subjects will be randomized into three subgroups, including vaccine group, adjuvant group and normal saline group, with randomization ratio of 2:2:1. The older cohort (aged 50 years and older) will consist of 72 subjects, 36 per dose level, and these 36 subjects will be randomized into four subgroups, including vaccine group, adjuvant group, Shingrix® group and normal saline group, with randomization ratio of 2:2:1:1.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low dose vaccine group in adults aged 18 to 49 years | Experimental | Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| Low dose adjuvant group in adults aged 18 to 49 years | Experimental | Subjects aged 18 to 49 years will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| High dose vaccine group in adults aged 18 to 49 years | Experimental | Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| High dose adjuvant group in adults aged 18 to 49 years | Experimental | Subjects aged 18 to 49 years will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| Placebo group in adults aged 18 to 49 years | Placebo Comparator |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Low Dose Recombinant Herpes Zoster Vaccine (CHO cells) | Biological | 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105. |
| Measure | Description | Time Frame |
|---|---|---|
| The incidence and severity of adverse events | Incidence and severity of adverse events within 30 minutes after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5. | Within 30 minutes after each vaccination. |
| The incidence and severity of adverse events | Incidence and severity of adverse events within 7 days after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5. | Within 7 days after each vaccination. |
| The incidence and severity of adverse events | Incidence and severity of adverse events during Day 8 to 30 after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5. | Day 8 to 30 after each vaccination. |
| The incidence and severity of adverse events | Incidence and severity of adverse events within 30 days after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5. | Within 30 days after each vaccination. |
| Incidence of abnormal and clinically significant laboratory test results | Laboratory test includes hematology, blood biochemistry and urine analysis. | Day 4 after each vaccination . |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Serious Adverse Event | Incidence of Serious Adverse Event (SAE) from the first vaccination to 12 months after full vaccination. | From the first vaccination to 12 months after full vaccination (From Day 0 to Day 420). |
| Potential Immune Mediated Disorder |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yanxia Wang | Henan Center for Disease Control and Prevention | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yanjin District Center for Disease Control and Prevention | Xinxiang | Henan | 453200 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Subjects aged 18 to 49 years will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| Low dose vaccine group in adults aged 50 years and older | Experimental | Subjects aged 50 years and older will be vaccinated with 2 doses of low dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| Low dose adjuvant group in adults aged 50 years and older | Experimental | Subjects aged 50 years and older will be vaccinated with 2 doses of low dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| High dose vaccine group in adults aged 50 years and older | Experimental | Subjects aged 50 years and older will be vaccinated with 2 doses of high dose recombinant herpes zoster vaccine (CHO cells) on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| High dose adjuvant group in adults aged 50 years and older | Experimental | Subjects aged 50 years and older will be vaccinated with 2 doses of high dose adjuvant on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| Shingrix® group in adults aged 50 years and older | Active Comparator | Subjects aged 50 years and older will be vaccinated with 2 doses of Shingrix® on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| Placebo group in adults aged 50 years and older | Placebo Comparator | Subjects aged 50 years and older will be vaccinated with 2 doses of placebo on a 0, 2 month schedule, administered intramuscularly (IM). |
|
| High Dose Recombinant Herpes Zoster Vaccine (CHO cells) | Biological | 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105. |
|
| Low dose adjuvant | Biological | 0.5 mL per dose, containing low dose MA105 adjuvant. |
|
| High dose adjuvant | Biological | 0.5 mL per dose, containing high dose MA105 adjuvant. |
|
| Positive control | Biological | 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B. |
|
|
| Placebo | Biological | 0.5 mL per dose, containing 4.5 mg sodium chloride. |
|
|
Incidence of Potential Immune Mediated Disorder (pIMD) from the first vaccination to 12 months after full vaccination. |
| From the first vaccination to 12 months after full vaccination (From Day 0 to Day 420). |
| Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody | Measured by ELISA. | Prior to each vaccination (Day 0, Day 60). |
| Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody | Measured by ELISA. | Day 14 after each vaccination (Day 14, Day 74). |
| Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody | Measured by ELISA. | Month 1 after each vaccination (Day 30, Day 90). |
| Geometric mean concentration (GMC) of anti-gE antibody and anti-VZV antibody | Measured by ELISA. | Month 6 and 12 after the second vaccination (Day 240, Day 420). |
| Seroconversion rate of anti-gE antibody and anti-VZV antibody | Seroconversion is defined as a ≥4 fold rise in antibody concentration compared with baseline for those antibody concentration was ≥Cut-off value at baseline; or a ≥4 fold Cut-off value in antibody concentration compared with baseline for those antibody concentration was \ | Prior to the second vaccination (Day 60). |
| Seroconversion rate of anti-gE antibody and anti-VZV antibody | Seroconversion is defined as a ≥4 fold rise in antibody concentration compared with baseline for those antibody concentration was ≥Cut-off value at baseline; or a ≥4 fold Cut-off value in antibody concentration compared with baseline for those antibody concentration was \ | Day 14 after each vaccination (Day 14, Day 74). |
| Seroconversion rate of anti-gE antibody and anti-VZV antibody | Seroconversion is defined as a ≥4 fold rise in antibody concentration compared with baseline for those antibody concentration was ≥Cut-off value at baseline; or a ≥4 fold Cut-off value in antibody concentration compared with baseline for those antibody concentration was \ | Month 1 after each vaccination (Day 30, Day 90). |
| Positive rate of anti-gE antibody and anti-VZV antibody | Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value. | Prior to each vaccination (Day 0, Day 60). |
| Positive rate of anti-gE antibody and anti-VZV antibody | Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value. | Day 14 after each vaccination (Day 14, Day 74). |
| Positive rate of anti-gE antibody and anti-VZV antibody | Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value. | Month 1 after each vaccination (Day 30, Day 90). |
| Positive rate of anti-gE antibody and anti-VZV antibody | Positive rate is defined as percentage of subjects with antibody concentration ≥Cut-off value. | Month 6 and 12 after the second vaccination (Day 240, Day 420). |
| Geometric mean increase(GMI) of anti-gE antibody and anti-VZV antibody concentration | The antibody concentration prior to the second vaccination compared with that at baseline (Day 0). | Prior to the second vaccination (Day 60). |
| Geometric mean increase(GMI) of anti-gE antibody and anti-VZV antibody concentration | The antibody concentration at Day 14 after each vaccination compared with that at baseline (Day 0). | Day 14 after each vaccination (Day 14, Day 74). |
| Geometric mean increase(GMI) of anti-gE antibody and anti-VZV antibody concentration | The antibody concentration at 1 month after each vaccination compared with that at baseline (Day 0). | Month 1 after each vaccination (Day 30, Day 90) |
| Four-fold increase rate of the anti-gE antibody and anti-VZV antibody concentration | The antibody concentration prior to the second vaccination compared with that at baseline (Day 0). | Prior to the second vaccination (Day 60). |
| Four-fold increase rate of the anti-gE antibody and anti-VZV antibody concentration | The antibody concentration at Day 14 after each vaccination compared with that at baseline (Day 0). | Day 14 after each vaccination (Day 14, Day 74). |
| Four-fold increase rate of the anti-gE antibody and anti-VZV antibody concentration | The antibody concentration at month 1 after each vaccination compared with that at baseline (Day 0). | Month 1 after each vaccination (Day 30, Day 90). |
| Frequency of gE-specific CD4+ T-cells expressing at least 1 Immunological activation marker | The analysis focused on CD4+ T-cells expressing at least 1 immunological activation marker among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). | Prior to the first vaccination (Day 0). |
| Frequency of gE-specific CD4+ T-cells expressing at least 1 Immunological activation marker | The analysis focused on CD4+ T-cells expressing at least 1 immunological activation marker among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). | Month 1 after the second vaccination (Day 90). |
| Frequency of gE-specific CD4+ T-cells expressing at least 1 Immunological activation marker | The analysis focused on CD4+ T-cells expressing at least 1 immunological activation marker among Interferon gamma (IFN-γ), Interleukin 2 (IL-2), Tumour Necrosis Factor alpha (TNF-α) and CD40 Ligand (CD40L). | Month 6, 12 after the second vaccination (Day 240, Day 420). |
| Cellular immune response | Cellular immune response is defined as the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥2 fold increase compared with baseline for those the frequency of gE-specific CD4+ T-cells ≥Cut-off value at baseline; or the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥Cut-off value for those the frequency of gE-specific CD4+ T-cells \ | Prior to the first vaccination (Day 0). |
| Cellular immune response | Cellular immune response is defined as the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥2 fold increase compared with baseline for those the frequency of gE-specific CD4+ T-cells ≥Cut-off value at baseline; or the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥Cut-off value for those the frequency of gE-specific CD4+ T-cells \ | Month 1 after the second vaccination (Day 90). |
| Cellular immune response | Cellular immune response is defined as the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥2 fold increase compared with baseline for those the frequency of gE-specific CD4+ T-cells ≥Cut-off value at baseline; or the frequency of gE-specific CD4+ T-cells (expressing at least 1 Immunological activation marker) ≥Cut-off value for those the frequency of gE-specific CD4+ T-cells \ | Month 6, 12 after the second vaccination (Day 240, Day 420) |
| ID | Term |
|---|---|
| D006562 | Herpes Zoster |
| ID | Term |
|---|---|
| D000073618 | Varicella Zoster Virus Infection |
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000277 | Adjuvants, Pharmaceutic |
| D012965 | Sodium Chloride |
| D007267 | Injections |
| ID | Term |
|---|---|
| D010592 | Pharmaceutic Aids |
| D004364 | Pharmaceutical Preparations |
| D020313 | Specialty Uses of Chemicals |
| D020164 | Chemical Actions and Uses |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
Not provided
Not provided